Reducing High Blood Cholesterol Level With Drugs
- 19 December 1990
- journal article
- research article
- Published by American Medical Association (AMA)
- Vol. 264 (23), 3025-3033
- https://doi.org/10.1001/jama.1990.03450230061030
Abstract
We performed a cost-effectiveness analysis of pharmacologic treatment of high blood cholesterol levels. Agents modeled were cholestyramine, colestipol, gemfibrozil, lovastatin, niacin, and probucol. Pharmacologic effectiveness was estimated from reported studies. Cost estimates reflect societal resource consumption. Annual costs for therapy ranged from $327 (niacin) to $1881 (lovastatin, 80 mg/d). Niacin was the most efficient agent for reducing low-density lipoprotein cholesterol levels, having an average cost over 5 years of $139 per percent reduction in low-density lipoprotein cholesterol level. Lovastatin (20 mg/d) was also efficient ($177 per percent reduction). Cholestyramine was least efficient at $347. For high-density lipoprotein cholesterol, niacin was most efficient, at $116 per percent increase in high-density lipoprotein cholesterol level, followed by gemfibrozil at $271. Analyses combining low-density lipoprotein cholesterol and high-density lipoprotein cholesterol effects suggest that niacin and lovastatin (20mg/d) were most efficient for reducing cardiovascular risk. (JAMA. 1990;264:3025-3033)Keywords
This publication has 16 references indexed in Scilit:
- Clinical economics. A guide to the economic analysis of clinical practicesJAMA, 1989
- A Multicenter Comparison of Lovastatin and Cholestyramine Therapy for Severe Primary HypercholesterolemiaPublished by American Medical Association (AMA) ,1988
- Meta-Analysis in Clinical ResearchAnnals of Internal Medicine, 1987
- Gemfibrozil in the Treatment of Dyslipidaemias in Middle‐Aged Male Survivors of Myocardial InfarctionActa Medica Scandinavica, 1981
- Probucol in hypercholesterolemia *1A double blind studyAtherosclerosis, 1980
- Cholesterol-lowering effect of colestipol hydrochloride given twice daily in hypercholesterolemic patientsAtherosclerosis, 1976
- Probucol: A new cholesterol‐lowering drug effective in patients with type II hyperlipoproteinemiaClinical Pharmacology & Therapeutics, 1976
- Probucol in the long-term treatment of hypercholesterolaemiaCurrent Medical Research and Opinion, 1973
- Colestipol and cholestyramine resin. Comparative effects in familial type II hyperlipoproteinemiaJAMA, 1972
- The U.S. Veterans Administration Cardiology Drug-Lipid Study: An Interim ReportPublished by Springer Science and Business Media LLC ,1969